ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

Nippon Shinyaku Co., Ltd.

Business Summary

Nippon Shinyaku Co., Ltd. engages in the manufacture and sale of pharmaceuticals and foodstuffs. Its operations are carried out through the Pharmaceuticals and Functional Food divisions. The Pharmaceuticals division develops and distributes drugs that treat urological diseases, inflammation, allergies, hematological malignancies, cardiovascular and metabolic diseases, and gastrointestinal disorders. The Functional Food division manufactures and supplies health food ingredients, preservatives, protein preparations, nutritional ingredients, seasonings and spices, and sterilization cleaning agents. The company was founded on November 20, 1911 and is headquartered Kyoto, Japan.

Financial Highlights

Mar 2022 JPYUSD
Revenue137,547M1,224.02M
Gross Profit85,981M765.14M
Operating income28,299M251.83M
Income before tax33,301M296.34M
Net income24,986M222.34M
EBITDA32,887M292.66M
Diluted EPS370.973.30
Dividends Per Share1100.97
Total Assets219,943M1,812.09M
Total liabilities39,055M321.77M
Total equity180,585M1,487.82M
Operating cash flow21,316M189.69M
Currency in JPYCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 101,448M 114,716M 116,637M 121,885M 137,547M
Gross Profit 54,061M 63,415M 63,130M 71,134M 85,981M
Operating income 17,080M 20,645M 21,669M 26,135M 28,299M
Income before tax 17,451M 21,540M 22,442M 27,608M 33,301M
Net income 12,954M 16,303M 16,866M 19,541M 24,986M
EBITDA 19,853M 24,063M 25,137M 30,535M 32,887M
Diluted EPS 192.30 242.03 250.41 290.11 370.97
Dividends Per Share 52 70 86 99 110
Total Assets 155,887M 168,763M 175,017M 205,446M 219,943M
Total liabilities 30,197M 33,571M 29,254M 41,994M 39,055M
Total equity 125,452M 134,937M 145,491M 163,161M 180,585M
Operating cash flow 6,719M 15,310M 12,737M 23,666M 21,316M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 915.32M 1,034.45M 1,072.76M 1,149.23M 1,224.02M
Gross Profit 487.77M 571.84M 580.63M 670.71M 765.14M
Operating income 154.10M 186.16M 199.29M 246.42M 251.83M
Income before tax 157.45M 194.23M 206.40M 260.31M 296.34M
Net income 116.87M 147.01M 155.12M 184.24M 222.34M
EBITDA 179.12M 216.98M 231.19M 287.91M 292.66M
Diluted EPS 1.73 2.18 2.30 2.73 3.30
Dividends Per Share 0.46 0.63 0.79 0.93 0.97
Total Assets 1,465.79M 1,524.71M 1,621.20M 1,859.23M 1,812.09M
Total liabilities 283.93M 303.30M 270.98M 380.03M 321.77M
Total equity 1,179.61M 1,219.10M 1,347.70M 1,476.57M 1,487.82M
Operating cash flow 60.62M 138.05M 117.14M 223.14M 189.69M

Valuation Measures

Mar 2022
PER22.45
ROA11.74%
ROE14.53%
Operating margin20.57%
Profit margin18.16%

Key executives

  • President & Representative Director: Toru Nakai
  • Manager-Accounting & Finance: Hideyuki Fujii
  • Director, Head-Research & Development: Kazuchika Takagaki
  • Director, Head-Risk & Compliance: Takashi Takaya
  • Executive Officer & Manager-Human Resources: Koji Honma

Shareholders

  • Meiji Yasuda Life Insurance Co. (9.2%)
  • Mitsubishi UFJ Financial Group, Inc. (5.8%)
  • Artisan Partners LP (4.9%)
  • The Bank of Kyoto, Ltd. (4.3%)
  • Nippon Shinyaku Co., Ltd. (4.1%)
  • Asset Management One Co., Ltd. (3.9%)
  • Nomura Asset Management Co., Ltd. (3.0%)
  • Wellington Management Co. LLP (2.8%)
  • FIL Investments (Japan) Ltd. (2.1%)
  • Nippon Life Insurance Co. (1.9%)

Contact Details

Related Companies

  • NS Pharma, Inc.
  • SIOE Pharmaceutical Co., Ltd.
  • Functional Food Co.
  • Nippon Shinyaku Employee Stock Ownership Plan

Competitors

  • Mezzion Pharma Co., Ltd.
  • Geron Corporation
  • Dyne Therapeutics Inc
  • Edgewise Therapeutics, Inc.
  • Entrada Therapeutics Inc
  • Sarepta Therapeutics, Inc.
  • Avidity Biosciences Inc
  • PTC Therapeutics, Inc.
  • Antisense Therapeutics Limited
  • United Therapeutics Corporation
  • Wave Life Sciences Ltd.
Last Updated on 10 Aug, 2022

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more